Enter assignee name

Trademarks = 2

Forward Citations = 7

Loading Chart...

14 inventors (with patents filed for the assignee):

Joshua Courtney Horan (6 out of 6 patents)

Scot Richard Mente (5 out of 29 patents)

Matthew D Shair (5 out of 23 patents)

4. Henry Efrem Pelish (5 out of 12 patents)

5. Anupong Tangpeerachaikul (5 out of 5 patents)

6. Xinxing Tang (4 out of 4 patents)

7. Baudouin Gerard (2 out of 8 patents)

8. Sibao Chen (1 out of 4 patents)

9. David James Pearson (1 out of 1 patent)

10. Benjamin Stephen Lane (1 out of 1 patent)

11. Jason T Kropp (1 out of 1 patent)

12. Christopher G F Cooper (1 out of 1 patent)

13. Kristin Lynne Andrews (1 out of 1 patent)

14. Yuting Sun (1 out of 1 patent)

6 patents: Sort by Forward Citations

1. 12275742 - Heteroaromatic macrocyclic ether chemotherapeutic agents (2025-04-14),

2. 12054498 - Heteroaromatic macrocyclic ether chemotherapeutic agents (2024-08-06),

3. 12043626 - Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds (2024-07-23),

4. 12037346 - Amino-substituted heteroaryls for treating cancers with EGFR mutations (2024-07-16),

5. 11667649 - Heteroaromatic macrocyclic ether chemotherapeutic agents (2023-06-06),

6. 11542278 - Heteroaromatic macrocyclic ether chemotherapeutic agents (2023-01-03),

Nuvalent, Inc. is a biotechnology company focused on developing novel targeted therapies for cancer. With a team of experienced scientists and researchers, Nuvalent is dedicated to advancing precision medicine and improving outcomes for cancer patients. The company's innovative approach to drug discovery and development has the potential to revolutionize cancer treatment and make a lasting impact on the field of oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

6 Patents

#292 in Cambridge, MA

#2,474 in Massachusetts

#43,823 in US

Cambridge, MA, United States of America

Nuvalent, Inc.